Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) said that the confirmatory Phase 3 TROPiCS-04 study of Trodelvy in locally advanced or metastatic urothelial cancer did not meet the primary
Foreign Affairs Provides up to the minute Raw News, reportage, current affairs, Open Source Intelligence, OSI, Information, Analysis, and Essays, all published with immediacy at the time of relevancy
FDA approved Bkemv as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH); and atypical hemolytic uremic syndrome (aHUS).
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior...
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.